Advances in Translational Neuropathic Research: Example of Enantioselective Pharmacokinetic–Pharmacodynamic Modeling of Ketamine-induced Pain Relief in Complex Regional Pain Syndrome

• Published in: Current pain and headache reports Vol. 15; no. 3; pp. 207 - 214
• Main Authors: Sabia, Michael, Hirsh, Robert A., Torjman, Marc C., Wainer, Irving W., Cooper, Niti, Domsky, Richard, Goldberg, Michael E.
• Format: Journal Article
• Language: English
• Published: New York Current Science Inc 01.06.2011; Springer Nature B.V
• Subjects: Animals; Complex Regional Pain Syndromes - drug therapy; Complex Regional Pain Syndromes - metabolism; Drug Evaluation, Preclinical - trends; Humans; Internal Medicine; Ketamine; Ketamine - chemistry; Ketamine - pharmacology; Ketamine - therapeutic use; Medicine; Medicine & Public Health; Models, Biological; Pain; Pain Measurement - drug effects; Pain Measurement - trends; Pain Medicine; Pharmacodynamics; Pharmacokinetics; Translational Medical Research - trends; (R,S) Norketamine; Pharmacodynamics; Enantioselective; Complex regional pain syndrome; Hydroxylated metabolites; Cytochromes; (R,S) Ketamine; NMDA receptor; Pharmacokinetics; Dehydronorketamine; Neuropathic pain
• ISSN: 1531-3433; 1534-3081
• DOI: 10.1007/s11916-011-0185-3

Historically, complex regional pain syndrome (CRPS) was poorly defined, which meant that scientists and clinicians faced much uncertainty in the study, diagnosis, and treatment of the syndrome. The problem could be attributed to a nonspecific diagnostic criteria, unknown pathophysiologic causes, and limited treatment options. The two forms of CRPS still are painful, debilitating disorders whose sufferers carry heavy emotional burdens. Current research has shown that CRPS I and CRPS II are distinctive processes, and the presence or absence of a partial nerve lesion distinguishes them apart. Ketamine has been the focus of various studies involving the treatment of CRPS; however, currently, there is incomplete data from evidence-based studies. The question as to why ketamine is effective in controlling the symptoms of a subset of patients with CRPS and not others remains to be answered. A possible explanation to this phenomenon is pharmacogenetic differences that may exist in different patient populations. This review summarizes important translational work recently published on the treatment of CRPS using ketamine.